Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Chemotherapy
Clinical trial register · China

Chemotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Beijing 5 Shanghai 5 Xi'an 3 Shaoguan 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Beijing5 Shanghai5 Xi'an3 Shaoguan3
All 27 locations
Target enrolment
to

Chemotherapy trials in China

41 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Tianjin Medical University Second Hospital
Phase 2
150
Tianjin, Xingtai
2026-10-20
Not yet open
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer
NCT07644533Electroacupuncture, Chemotherapy, Advanced Cancer, Peripheral Neuropathy
Affiliated Hospital of Qinghai University
Not applicable
264
Xining
2026-05-25
Not yet open
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer
NCT07663396Electroacupuncture, Chemotherapy, Peripheral Neuropathy, Early Stage Cancer
Affiliated Hospital of Qinghai University
Not applicable
278
Xining
2026-05-25
Not yet open
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07561983Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
Sichuan Cancer Hospital and Research Institute
Phase 2
39
Chengdu
2026-05-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Not yet open
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
29
Nanjing
2025-12-01
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
106
Hangzhou
2025-07-16
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Recruiting
Fudan University
Phase 2
100
Shanghai
2025-04-01
Recruiting
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
NCT06542549Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy
Anhui Provincial Hospital
Phase 3
100
Hefei
2025-03-11
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Recruiting
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Not yet open
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
NCT06673459T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
The First Affiliated Hospital of Soochow University
Phase 3
430
Suzhou
2024-12-01
Not yet open
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
By invitation
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
NCT06688175Nasopharyngeal Neoplasms, Elderly, Chemotherapy
DrugIMRT
The First Affiliated Hospital of Xiamen University
Phase 2
32
Xiamen
2024-11-13
Recruiting
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
90
Yiwu
2024-10-30
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
Zibo Municipal Hospital
Phase 2
20
Zibo
2024-01-13
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xi’an
2022-08-01
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05125055Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
Shanghai Jiao Tong University School of Medicine
Phase 2/3
80
Shanghai
2021-10-01
Not yet open
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04891016Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2021-06-25
Active, closed
Tang-Du Hospital
Phase 2
45
Xi'an
2021-03-01
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Recruiting
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Recruiting
Colorectal Cancer Dataset in Xijing Hospital From 2011
NCT06308354Prognostic Cancer Model, Chemotherapy, Nutrition Related Cancer
Xijing Hospital
Observational
40,000
Xi'an
2011-01-01
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/chemotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies listing the condition Chemotherapy.

How many Chemotherapy trials are recruiting in China?

27 of the 41 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chemotherapy), 41 studies
PhaseStudiesRecruitingShare
Phase 2201348.8%
Phase 37517.1%
Not applicable5312.2%
Observational337.3%
Phase 2/3317.3%
Phase 1/2214.9%
Phase 1112.4%

Most active sponsors

Lead sponsors with the most studies (Chemotherapy)
Lead sponsorStudiesRecruiting
Sun Yat-sen University96
Fudan University33
Affiliated Hospital of Qinghai University20
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Tang-Du Hospital21
Tao Zhang21
Zibo Municipal Hospital22
Anhui Provincial Hospital11
Henan Cancer Hospital11
Nanfang Hospital, Southern Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.